Atomoxetine
- Generic Name
- Atomoxetine
- Brand Names
- Strattera
- Drug Type
- Small Molecule
- Chemical Formula
- C17H21NO
- CAS Number
- 83015-26-3
- Unique Ingredient Identifier
- ASW034S0B8
- Background
Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associat...
- Indication
Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Associated Therapies
- -
Treatment of Orthostatic Hypotension in Autonomic Failure
- Conditions
- Interventions
- Drug: AtomoxetineDrug: placeboDrug: AcarboseDevice: inflatable abdominal binder (sham)Drug: Pyridostigmine BromideDrug: YohimbineDrug: Midodrine HClDrug: ModafinilDrug: OctreotideOther: water intakeDrug: Diphenhydramine HydrochlorideDrug: Ranitidine HCLDrug: TranylcypromineDrug: Ergotamine/ CaffeineDrug: CelecoxibDrug: PseudoephedrineDrug: MethylphenidateDrug: IndomethacinDrug: IbuprofenDrug: Oxymetazoline 0.05% nasal solutionDietary Supplement: BovrilDrug: AcetazolamideDrug: Rivastigmine tartrateDrug: Carbidopa/levodopaDevice: Inflatable abdominal binder
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 389
- Registration Number
- NCT00223691
- Locations
- 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 105
- Registration Number
- NCT00191048
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Burlington, Vermont, United States
An Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 257
- Registration Number
- NCT00191516
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Koln, Germany
An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 147
- Registration Number
- NCT00191737
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Koln, Germany
Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT00191633
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Summerside, Prince Edward Island, Canada
🇨🇦For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Saskatoon, Saskatchewan, Canada
Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-12-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 520
- Registration Number
- NCT00191035
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Nashville, Tennessee, United States
Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-10-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 100
- Registration Number
- NCT00191542
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Vaxjo, Sweden
Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-08-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 100
- Registration Number
- NCT00191880
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Toronto, Canada
Long-Term, Open Label Atomoxetine Study
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-01-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1553
- Registration Number
- NCT00190684
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sheffield, South Yorkshire, United Kingdom
Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 140
- Registration Number
- NCT00190957
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Vancouver, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.